An apolipoprotein formulation is provided at a fixed dosage that is efficacious in the prophylactic and/or therapeutic treatment of diseases or conditions including but not limited to cardiovascular disease acute coronary syndrome atherosclerosis unstable angina pectoris and myocardial infarction. More particularly the fixed dosage apolipoprotein formulation displays relatively reduced inter patient variability compared to weight adjusted dosages. Typically the apolipoprotein formulation is a reconstituted high density lipoprotein formulation comprising ApoA1 one or more lipids such as phosphatidylcholine sphingomyelin and/or phosphatidylglycerol and optionally a detergent such as cholate at a level that does not induce liver toxicity.
